Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

被引：0
|
作者：
Klein, Austin T. [1 ,2 ,3 ]
Mendillo, Marc L. [1 ,2 ,3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA
[2] Northwestern Univ, Simpson Querrey Ctr Epigenet, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CELL CHEMICAL BIOLOGY | 2023年 / 30卷 / 11期
关键词：
D O I：
10.1016/j.chembiol.2023.10.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resis-tance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combi-nation therapeutic strategies.
引用
收藏
页码：1334 / 1336
页数：3
相关论文
共 50 条
  • [31] CREB is required for KRAS-driven lung tumorigenesis
    Lee, Jong Woo
    Slack, Frank J.
    Nestler, Eric J.
    Herbst, Roy S.
    Koo, Jaseok Peter
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Metabolic vulnerability of KRAS-driven cancer cells
    Foster, David A.
    MOLECULAR & CELLULAR ONCOLOGY, 2014, 1 (03):
  • [33] Targeting the MAPK Pathway in KRAS-Driven Tumors
    Drosten, Matthias
    Barbacid, Mariano
    CANCER CELL, 2020, 37 (04) : 543 - 550
  • [34] PKCε Is Required for KRAS-Driven Lung Tumorigenesis
    Garg, Rachana
    Cooke, Mariana
    Benavides, Fernando
    Abba, Martin C.
    Cicchini, Michelle
    Feldser, David M.
    Kazanietz, Marcelo G.
    CANCER RESEARCH, 2020, 80 (23) : 5166 - 5173
  • [35] Targeting cytokine networks in KRAS-driven tumorigenesis
    Golay, Hadrien G.
    Barbie, David A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (08) : 869 - 871
  • [36] Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
    Mandar Deepak Muzumdar
    Kimberly Judith Dorans
    Katherine Minjee Chung
    Rebecca Robbins
    Tuomas Tammela
    Vasilena Gocheva
    Carman Man-Chung Li
    Tyler Jacks
    Nature Communications, 7
  • [37] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
    Adachi, Yuta
    Kimura, Ryo
    Hirade, Kentaro
    Ebi, Hiromichi
    CANCERS, 2021, 13 (20)
  • [38] The Role of an Intermediate Conformation of SHP2 in the MEK Pathway of KRAS-Driven Cancers
    Shannon, Daniel
    Poetker, Gavin
    Kaplan, Donnie
    Gruber, Weston
    Pease, Emmet
    McCloud, Brandon
    Allen, Jake
    Connolly, Connor
    Diao, JiaJie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S791 - S791
  • [39] Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers
    Hai, Josephine
    Liu, Shengwu
    Bufe, Lauren
    Do, Khanh
    Chen, Ting
    Wang, Xiaoen
    Ng, Christine
    Li, Shuai
    Tsao, Ming-Sound
    Shapiro, Geoffrey I.
    Wong, Kwok-Kin
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6993 - 7005
  • [40] A regulatory role for codon bias in KRAS-driven tumor progression and therapeutic resistance
    Kaltenbrun, Erin
    Ali, Moiez
    Stephens, Sarah Jo
    Counter, Christopher
    Wood, Kris
    CANCER RESEARCH, 2017, 77
12345